NMK-TD-100, a Novel Microtubule Modulating Agent, Blocks Mitosis and Induces Apoptosis in HeLa Cells by Binding to Tubulin

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Bhattacharya, Surela ^a   Kumar, N Maruthi ^b   Ganguli, Arnab ^a   Tantak, Mukund P ^b   Kumar, Dalip ^b   Chakrabarti, Gopal ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; ALPHA TUBULIN; COLCHICINE; MICROTUBULE PROTEIN; NMK TD 100; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL DISRUPTION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEPOLYMERIZATION; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; HELA CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; INHIBITION KINETICS; MICROTUBULE; MITOCHONDRIAL MEMBRANE; MITOSIS INDEX; MITOSIS INHIBITION; MOLECULAR MODEL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERIZATION; STOICHIOMETRY; TRYPTOPHAN METABOLISM;

AMINO ACIDS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; INDOLES; LEUKOCYTES, MONONUCLEAR; M PHASE CELL CYCLE CHECKPOINTS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, ELECTRON; MICROTUBULES; MITOSIS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; THIADIAZOLES; TUBULIN; TUBULIN MODULATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885077628     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076286     Document Type: Article

References (45)

1. Chhabra S, Bhavani M, Mahajan N, Bawaskar R, (2010) Cervical cancer in Indian rural women: trends over two decades. J Obstet Gynaecol 30: 725-728. doi:10.3109/01443615.2010.501412. PubMed: 20925620.
2. Canavan TP, Doshi NR, (2000) Cervical cancer. Am Fam Physician 61: 1369-1376. PubMed: 10735343.
3. FDA Approves First Drug Treatment for Late-Stage Cervical Cancer. U.S. Food and Drug Administration (2006)-06-15.
4. Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, et al. (2010) Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67: 1089-1094. doi:10.1007/s00018-009-0245-6. PubMed: 20107862.
5. Nogales E, Wang HW, (2006) Structural intermediates in microtubule assembly and disassembly: how and why? Curr Opin Cell Biol 18: 179-184. doi:10.1016/j.ceb.2006.02.009. PubMed: 16495041.
6. Kline-Smith SL, Walczak CE, (2004) Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. Mol Cell 15: 317-327. doi:10.1016/j.molcel.2004.07.012. PubMed: 15304213.
7. Jordan MA, Wilson L, (2004) Microtubule as a target for anticancer drugs. Nat Rev Cancer 4: 253-265. doi:10.1038/nrc1317. PubMed: 15057285.
8. Tian W, Qin L, Song Q, He L, Ai M, et al. (2010) A Novel Synthetic Analog of 5, 8-Disubstituted Quinazolines Blocks Mitosis and Induces Apoptosis of Tumor Cells by Inhibiting Microtubule Polymerization. PLOS ONE 5: 10499. doi:10.1371/journal.pone.0010499.
9. Torfs S, Cadron I, Amant F, Leunen K, Berteloot P, et al. (2012) Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. Eur J Cancer 48: 1332-1340. doi:10.1016/j.ejca.2012.01.006. PubMed: 22317951.
10. Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH, (2004) Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22: 340-344.
11. Acharya BR, Choudhury D, Das A, Chakrabarti G, (2009) Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry 48: 6963-6974. doi:10.1021/bi900152k. PubMed: 19527023.
12. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, et al. (1987) Expression of a multidrug-resistance gene in tumors and tissues. Proc Natl Acad Sci U S A 84: 265-269. doi:10.1073/pnas.84.1.265. PubMed: 2432605.
13. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, et al. (2005) Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 5: 57-68. doi:10.2174/1568009053332672. PubMed: 15720190.
14. Kumar D, Maruthi NK, Chang KH, Shah K, (2010) Synthesis and anticancer activity of 5-(3-indolyl)-1,3,4-thiadiazoles. Eur J Med Chem 45: 4664-4668. doi:10.1016/j.ejmech.2010.07.023. PubMed: 20692741.
15. Shen L, Zhang Y, Wang A, SieberMcMaster E, Chen X, et al. (2007) Synthesis and identification of Yanvar 2,4- thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta. J Med Chem 50: 3954-3963. doi:10.1021/jm070511x. PubMed: 17608467. doi:10.1021/jm070511x PubMed: 17608467.
16. Kadi AA, El-Brollosy NR, Al-Deeb OA, Habib EE, Ibrahim TM, et al. (2007) Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazolesand 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles. Eur J Med Chem 42: 235-342. doi:10.1016/j.ejmech.2006.10.003. PubMed: 17129641.
17. Turner S, Myers M, Gadie B, Nelson AJ, Pape R, et al. (1988) Antihypertensive thiadiazoles. 1. Synth Some: pp. 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity. J Med Chem 31: 902-907.
18. Foroumadi A, Mansouri S, Kiani Z, Rahmani A, (2003) Synthesis and in vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones. Eur J Med Chem 38: 851-854. doi:10.1016/S0223-5234(03)00148-X. PubMed: 14561484.
19. Dogan HN, Duran A, Rollas S, Sener G, Uysal MK, et al. (2002) Synthesis of new 2,5-disubstituted-1,3,4-thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities. Bioorg Med Chem 10: 2893-2898. doi:10.1016/S0968-0896(02)00143-8. PubMed: 12110309.
20. Yusuf M, Khan RA, Ahmed B, (2008) Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives. Bioorg Med Chem 16: 8029-8034. doi:10.1016/j.bmc.2008.07.056. PubMed: 18693019.
21. Poorrajab F, Ardestani SK, Emami S, Behrouzi-Fardmoghadam M, Shafiee A, et al. (2009) Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation. Eur J Med Chem 44: 1758-1762. doi:10.1016/j.ejmech.2008.03.039. PubMed: 18485538.
22. Padmavathi V, Sudhakar Reddy G, Padmaja A, Kondaiah P, Ali-Shazia, (2009) Synthesis, antimicrobial and cytotoxic activities of Yanvar 3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles. Eur J Med Chem 44: 2106-2112. doi:10.1016/j.ejmech.2008.10.012. PubMed: 19036476.
23. Matysiak J, (2007) Evaluation of electronic, lipophilic and membrane affinity effects on antiproliferative activity of 5-substituted-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles against various human cancer cells. Eur J Med Chem 42: 940-947. doi:10.1016/j.ejmech.2006.12.033. PubMed: 17320247.
24. Asbury R, Blessing JA, Moore D, (1996) A phase II trial of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study. Am J Clin Oncol 19: 400-402. doi:10.1097/00000421-199608000-00017. PubMed: 8677914.
25. Peifer C, Selig R, Kinkel K, Ott D, Totzke F, et al. (2008) Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. J Med Chem 51: 3814-3824. doi:10.1021/jm8001185. PubMed: 18529047.
26. Garuti L, Roberti M, Pession A, Leoncini E, Hrelia S, (2001) Synthesis and antiproliferative activity of some thiazolylbenzimidazole-4,7-diones. Bioorg Med Chem Lett 11: 3147-3149. doi:10.1016/S0960-894X(01)00639-4. PubMed: 11720862.
27. Hamel E, Lin CM, (1981) Glutamate-induced polymerization of tubulin: Characteristics of the reaction and application to the large scale purification of tubulin. Arch Biochem Biophys 209: 29-40. doi:10.1016/0003-9861(81)90253-8. PubMed: 6116478.
28. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. doi:10.1016/0003-2697(76)90527-3. PubMed: 942051.
29. Dariusz S, Sarah JS, Richard HC, Michael B, (1993) An improved MTT assay. J Immunol Methods 157: 203-207. doi:10.1016/0022-1759(93)90088-O. PubMed: 8423364.
30. Paino IM, Marangoni VS, de Oliveira Rde C, Antunes LM, Zucolotto V, (2012) Cyto and genotoxicity of gold nanoparticles in human hepatocellular carcinoma and peripheral bloodmononuclear cells. Toxicol Lett 215: 119-125. doi:10.1016/j.toxlet.2012.09.025. PubMed: 23046612.
31. Xie Z, Choong PF, Poon LF, Zhou J, Khng J,et al (2008) Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62: 949-957. doi:10.1007/s00280-008-0684-z. PubMed: 18259754.
32. Li J, Qin Z, Liang Z, (2009) The prosurvival role of autophagy in Resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer 9: 215. doi:10.1186/1471-2407-9-215. PubMed: 19566920.
33. Kamath K, Jordan MA, (2003) Suppression of microtubule dynamics by Epothilone B is associated with mitotic arrest. Cancer Res 63: 6026-6031. PubMed: 14522931.
34. Minotti AM, Barlow BS, Cabral F, (1991) Resistance to antimitotic drugs in chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Cell Biochem 266: 3987-3994. PubMed: 1671676.
35. Gaskin F, Cantor CR, Shelanski ML, (1974) Turbidimetric studies of the in vitro assembly and disassembly of porcine neurotubules. J Mol Biol 89: 737-755. doi:10.1016/0022-2836(74)90048-5. PubMed: 4475698.
36. Lakowicz JR, (1999) Principles of Fluorescence Spectroscopy, 2nd ed.New York: Kluwer Academic/Plenum Publishers.
37. Mas MT, Colman RF, (1985) Spectroscopic studies of the interactions of coenzymes and coenzyme fragments with pig heart, oxidized triphosphopyridine nucleotide specific isocitrate dehydrogenase. Biochemistry 24: 1634-1646. doi:10.1021/bi00328a011. PubMed: 3843532.
38. Ward LD, (1985) Measurement of ligand binding to protein by fluorescence spectroscopy. Methods Enzymol 117: 400-414. doi:10.1016/S0076-6879(85)17024-2. PubMed: 4079811.
39. Gupta KK, Bharne SS, Rathinasamy K, Naik NR, Panda D, (2006) Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J 273: 5320-5332. doi:10.1111/j.1742-4658.2006.05525.x. PubMed: 17069615.
40. Lambeir A, Engelborghs Y, (1981) A fluorescence stopped flow study of colchicine binding to tubulin. J Biol Chem 256: 3279-3282. PubMed: 7204403.
41. Löwe J, Li H, Downing KH, Nogales E, (2001) Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol 313: 1045-1057. doi:10.1006/jmbi.2001.5077. PubMed: 11700061.
42. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, et al. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin like domain. Nature 428: 198-202. doi:10.1038/nature02393. PubMed: 15014504.
43. Chattopadhyay A, Rawat SS, Kelkar DA, Ray S, Chakrabarti A, (2003) Organization and dynamics of tryptophan residues in erythroid spectrin: Novel structural features of denatured spectrin revealed by the wavelength-selective fluorescence approach. Protein Sci 12: 2389-2403. PubMed: 14573853.
44. Bhattacharyya B, Kapoor S, Panda D, (2010) Fluorescence spectroscopic methods to analyze drug-tubulin interactions. Methods Cell Biol 95: 301-329. doi:10.1016/S0091-679X(10)95017-6. PubMed: 20466142.
45. Banerjee A, Luduena RF, (1992) Kinetics of colchicine binding to purified β tubulin isotypes from bovine brain. J Biol Chem 267: 13335-13339. PubMed: 1618835.